David A. Siegel Precision Biosciences Inc Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.29 - $0.45 $145,029 - $225,045	500,100 New	500,100 $180,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $40.8 $32,574 - $1.09 Million	-26,700 Reduced 65.76%	13,900 $18,000
Q2 2022 Aug 15, 2022	SELL	$1.15 - $3.34 $45,655 - $132,598	-39,700 Reduced 49.44%	40,600 $65,000
Q1 2022 May 16, 2022	BUY	$2.96 - $7.76 $139,416 - $365,496	47,100 Added 141.87%	80,300 $247,000
Q4 2021 Feb 14, 2022	SELL	$7.4 - $11.66 $430,680 - $678,612	-58,200 Reduced 63.68%	33,200 $246,000
Q3 2021 Nov 15, 2021	BUY	$9.18 - $14.15 $429,624 - $662,220	46,800 Added 104.93%	91,400 $1.06 Million
Q2 2021 Aug 16, 2021	BUY	$8.07 - $12.52 $359,922 - $558,392	44,600 New	44,600 $558,000
Q1 2021 May 17, 2021	SELL	$8.57 - $15.79 $347,942 - $641,074	-40,600 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $1.18 Million - $2.45 Million	-196,600 Reduced 82.88%	40,600 $339,000
Q3 2020 Nov 16, 2020	BUY	$4.65 - $8.73 $702,615 - $1.32 Million	151,100 Added 175.49%	237,200 $1.46 Million
Q2 2020 Aug 14, 2020	BUY	$4.66 - $8.7 $265,620 - $495,899	57,000 Added 195.88%	86,100 $717,000
Q1 2020 May 15, 2020	BUY	$5.05 - $15.01 $146,955 - $436,791	29,100 New	29,100 $175,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $578M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.